Actively Recruiting
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Led by MegaPro Biomedical Co. Ltd. · Updated on 2025-11-03
81
Participants Needed
1
Research Sites
194 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.
CONDITIONS
Official Title
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent before any study procedure.
- Male or female patients aged 18 years or older.
- Confirmed measurable solid tumor lesions that are unresectable and lack effective standard therapy.
- Eastern Cooperative Oncology Group Performance Status of 2 or less.
- Recovery from acute toxicity of previous therapies except alopecia, with specific timeframes since last treatment:
- At least 4 weeks since surgery, endocrine therapy, tyrosine kinase inhibitors, immunotherapy, radiotherapy, or chemotherapy.
- At least 6 weeks since chemotherapy with nitrosoureas, melphalan, or mitomycin C.
- At least 6 weeks since cranial radiotherapy.
- Life expectancy greater than 12 weeks.
- Ability to communicate and comply with study requirements in the local language.
You will not qualify if you...
- Peripheral sensory neuropathy greater than Grade 2 at baseline.
- Need for immediate palliative treatment including surgery or radiotherapy.
- Serum bilirubin greater than 1.5 times the upper limit of normal.
- AST and/or ALT greater than 2.5 times upper limit if no liver involvement, or greater than 5 times with liver involvement.
- Serum creatinine greater than 1.5 times upper limit or creatinine clearance less than 50 mL/min.
- QTc interval 470 ms or longer or significant ECG abnormalities.
- Known allergy to taxanes or any drug components.
- Female patients who are pregnant, breastfeeding, or planning pregnancy during the study.
- Untreated or uncontrolled central nervous system metastases.
- Having brain tumors, primary or metastatic.
- Use of medications expected to cause drug interactions.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Taipei Veterans General Hospital
Taipei, Taiwan, 112
Actively Recruiting
Research Team
S
Summer Liao, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here